 Pyridines
"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1983 | 2 | 0 | 2 | | 1985 | 2 | 0 | 2 | | 1987 | 2 | 0 | 2 | | 1988 | 1 | 0 | 1 | | 1989 | 2 | 0 | 2 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 1 | 2 | 3 | | 1995 | 1 | 2 | 3 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 4 | 2 | 6 | | 1999 | 2 | 1 | 3 | | 2000 | 4 | 1 | 5 | | 2001 | 3 | 6 | 9 | | 2002 | 2 | 0 | 2 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 4 | 5 | | 2005 | 1 | 6 | 7 | | 2006 | 4 | 1 | 5 | | 2007 | 5 | 5 | 10 | | 2008 | 5 | 3 | 8 | | 2009 | 9 | 5 | 14 | | 2010 | 14 | 5 | 19 | | 2011 | 11 | 2 | 13 | | 2012 | 6 | 5 | 11 | | 2013 | 6 | 4 | 10 | | 2014 | 6 | 2 | 8 | | 2015 | 7 | 2 | 9 | | 2016 | 8 | 5 | 13 | | 2017 | 4 | 4 | 8 | | 2018 | 6 | 6 | 12 | | 2019 | 1 | 6 | 7 | | 2020 | 3 | 3 | 6 | | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021 09; 32(9):1101-1110.
-
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
-
Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN, Saraiya B, Pal SK, Stein MN, Mortazavi A. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 11 01; 38(31):3672-3684.
-
Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, Cao L, Parnes HL, Costello R, Merino MJ, Folio LR, Lindenberg L, Raffeld M, Lin J, Lee MJ, Lee S, Alarcon SV, Yuno A, Dawson NA, Allette K, Roy A, De Silva D, Lee MM, Sissung TM, Figg WD, Agarwal PK, Wright JJ, Ning YM, Gulley JL, Dahut WL, Bottaro DP, Trepel JB. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 2020 08; 21(8):1099-1109.
-
Ruan T, Sun J, Liu W, Prinz RA, Peng D, Liu X, Xu X. H1N1 Influenza Virus Cross-Activates Gli1 to Disrupt the Intercellular Junctions of Alveolar Epithelial Cells. Cell Rep. 2020 06 30; 31(13):107801.
-
Chen Q, Rehman J, Chan M, Fu P, Dudek SM, Natarajan V, Malik AB, Liu Y. Angiocrine Sphingosine-1-Phosphate Activation of S1PR2-YAP Signaling Axis in Alveolar Type II Cells Is Essential for Lung Repair. Cell Rep. 2020 06 30; 31(13):107828.
-
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
-
Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AM. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res. 2020 06 01; 26(11):2477-2486.
-
Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53.
-
Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020 02 15; 26(4):804-811.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|